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Abstract
Organophosphate esters (OPEs) are often used as flame retardants and plasticizers. Animal data 
suggest exposure OPEs could impact children’s growth and development, yet impacts on human 
birth outcomes are understudied. We evaluate impacts of OPE exposure on the timing of delivery 
and infant’s birthweight in the Pregnancy Infection and Nutrition Study (PIN). North Carolina 
women enrolled in PIN in early pregnancy and conducted follow-up through delivery. Analyses 
were limited to mothers recruited 2002–2005, whose children participated in follow-up (n=349). 
Mothers collected urine samples in which OPE metabolites were assessed and birth outcomes 
were abstracted from medical records. Bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), diphenyl 
phosphate (DPHP), isopropyl-phenyl phenyl phosphate (ip-PPP), bis(1-chloro-2-propyl) 1-
hydroxy-2-propyl phosphate (BCIPHIPP) were detected in >80% of samples. Average birthweight 
and gestational age were 3326 g and 39.1 weeks, respectively. As data suggest that the 
mechanisms of action by which OPEs impact birth outcomes may be fetal sex dependent, we 
conducted sex-stratified statistical analyses. Women with the highest ip-PPP concentrations 
delivered girls 1 week earlier than women with lower levels (95% Confidence Interval (CI): −1.9, 
−0.2). Women with BDCIPP levels above the median had 3.99 (95% CI: 1.08, 14.78) times the 
odds of delivering their daughters preterm. Similarly, higher ip-PPP levels were associated with 
lower birthweight, but not after standardizing for gestational age. Among males, maternal ip-PPP 
was associated with decreased odds of preterm birth (OR=0.21, 95% CI: 0.06, 0.68). DPHP and 
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BCIPHIPP levels were not associated with outcomes in either sex. Results indicate that prenatal 
OPE exposure may impact timing of birth, though results are imprecise. Given the widespread 
OPEs exposure and the urgent need to identify and mitigate causes of preterm birth, further 
investigation is warranted.
Introduction
Organophosphate compounds are commonly detected in indoor environments, owing in part 
to their widespread use as flame retardant chemicals (FRs). For example, tris (1,3-
dichloropropyl) phosphate (TDCIPP) is commonly detected in polyurethane foam samples 
from residential furniture and baby products (e.g. car seats and nursing pillows 1–4). Other 
organophosphates, including triphenyl phosphate (TPHP) are used as FRs in furniture, 
electronics, and construction materials and are also used in other applications as plasticizers.
1,5–9 Organophosphate esters (OPEs) are not chemically bound to the products in which they 
are used and as a result they are predisposed to migrate into the environment, chronically 
exposing the vast majority of the general population. OPEs are thought to be metabolized 
relatively quickly by the human body (t½~hours)9–11 and measures of urinary metabolites 
are used as indicators of exposure. Numerous studies demonstrate that >90% of the 
population has detectable levels of OPE metabolites in their urine, e.g. 12–15 and some data 
indicate that pregnant women may have higher levels of OPE metabolites in their urine.12 
Data suggest OPEs can be transferred from the mother to her child in utero. 16–18 TPHP was 
detected in placenta samples of dose rats and both TDCIPP and TPHP have been detected in 
human placenta samples.17,18 OPEs also have been detected in human chronic villi and 
deciduae, suggesting transfer early in gestation (i.e. prior to the formation of a mature 
placenta).16
Toxicological studies suggest that exposure to OPEs may affect reproductive health and 
children’s early-life growth and development.19–32 For example, chicken embryos exposed 
to TDCIPP were observed to have a 7% decrease in weight at hatching29 and prenatal 
exposure to TDCIPP has been shown to increase the number of visibly small rat pups (i.e. 
runt pups) and significantly impacted weight gain through weaning.30 In addition, perinatal 
exposure to Firemaster® 550, a flame retardant mixture containing organophosphate [TPHP 
and isopropylated triaryl phosphates (ITPs)] and brominated compounds (2-
ethylhexyl-2,3,4,5-tetrabromobenzoate and bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate) 
has been associated with rapid weight gain in rat pups and obesity in adult rats, raising 
concern about potential impacts of FM 550’s components, including OPEs on early growth.
19 Gestational duration and potential impacts of OPEs on preterm birth risk have not been 
investigated in toxicological studied, due in part to the tightly controlled timing of 
parturition in most animal species. Epidemiologic data investigating potential reproductive 
and development impacts of OPE exposure are limited. Endocrine disruption has been 
reported 33–35, suggesting a possible mechanism by which OPEs could alter fetal growth or 
impact the gestational duration. In the only study of human birth outcomes, OPE metabolite 
concentrations were negatively associated with pregnancy outcomes (i.e. proportions of 
successful fertilization, implantation, clinical pregnancy, and live birth) among women 
undergoing fertility treatment urinary.36
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We hypothesize that prenatal exposure to OPEs alters the timing of labor or fetal growth. 
Using data from the Pregnancy Infection and Nutrition Study (PIN) we test this hypothesis 
by investigating potential associations between biomarkers of prenatal OPE exposures and 
birth outcomes (i.e. gestational timing and preterm birth as well as birthweight-for-
gestational age). Given the demonstrated male vulnerability to prenatal environmental 
exposures, the sex-specific adaptation of the placenta, and established differences in the 
impact of endocrine perturbations by sex, we evaluated the potential for OPEs to impact 
birth outcomes in a sex specific manner 37–40. To our knowledge, these are the first data 
investigating relationships between OPEs and fetal growth and the timing parturition.
Methods
Study population
The PIN Study enrolled a cohort of central North Carolina women in early pregnancy and 
conducted follow-up through delivery.41 Pregnant women were recruited from the University 
of North Carolina prenatal care clinic, and delivered their infants at University of North 
Carolina hospitals between 2001 and 2006 (n=2006). The analysis sample for this work is 
limited to children who were singleton births, free from major birth defects, and whose 
mothers provided a prenatal urine sample. In addition, as this work is part of a larger project 
investigating post-natal development, urine samples were only analyzed from mothers with 
children participating in growth follow-up after birth as a part of the PIN Babies Study. PIN 
Babies began in January 2004 to follow the children of women participating in the later 
years of the PIN study through 3 years of age (n = 585 with n = 349 having growth 
information and included in the present analyses). Questionnaires and medical records were 
used to collect information about the pregnancy.41 All study protocols were approved by the 
institutional review board at the University of North Carolina at Chapel Hill and all mothers 
provided informed consent prior to completing any study activities.
OPE analysis
Urine collection and OPE analyses methods have been described in detail for these women 
previously.42 In brief, during the late-second or early-third trimester (gestational week 24–
30), women collected a spot urine sample which was aliquoted into polyethylene storage 
tubes and frozen at −80° C until analysis. Levels of six OPE metabolites were assessed in 
urine samples: BDCIPP, diphenyl phosphate (DPHP), isopropyl-phenyl phenyl phosphate 
(ip-PPP), bis(1-chloro-2-propyl) 1-hydroxy-2-propyl phosphate (BCIPHIPP), bis(2-chloro-
isopropyl) phosphate (BCIPP), and tert butyl-phenyl phenyl phosphate (tb-PPP). Samples 
were extracted and analyzed as previously described.42–44
Specific gravity (SG) was measured in each urine sample prior to analysis using a digital 
handheld refractometer (Atago). To investigate the impacts of differences in urine dilution 
on results, we conducted analyses of urinary metabolites using raw OPE metabolite 
measures as well as using SG-corrected concentrations.45 Corrected and uncorrected 
concentrations were very highly correlated (rs>0.82 for all metabolites) and results were 
very similar using both methods. Here we present only the results obtained with the SG 
corrected concentrations to facilitate comparison with other study populations.
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Gestational age in days was estimated using a combination of last menstrual period and 
earliest-ultrasounds data. When both measures were available and agreed within 14 days, the 
last menstrual period was used to assign gestational age; otherwise, ultrasound data were 
used. Birthweight was obtained from the medical record. Sex-specific birthweight-for-
gestational age z-scores were assigned using a calculator based on the 
INERTGROWTH-21st standards.46,47 In addition to continuous measures of gestational age, 
we used preterm birth (defined as <37 weeks gestation) as an outcome in analyses.
Statistical analyses
Previous analyses indicated that urinary OPE metabolite levels were positively skewed.42 
Relationships between OPEs and outcomes were evaluated when detection frequencies of 
metabolites were >80%. For these metabolites, samples with concentrations below the 
method limit of detection (MDL) were replaced with the MDL/2 prior to adjustment for SG.
We used multivariable regression models to assess relationship between OPEs and 
continuous measures of gestational duration and birthweight-for-gestational age z-scores. To 
allow for more flexible relationships between OPEs and birth outcomes, models were 
constructed with quartiles of OPE exposure. Birth outcome models were adjusted for 
maternal age, race, education, pre-pregnancy BMI, parity and season of urine samples 
collection, factors which we have previously shown are related to urinary OPE metabolite 
concentrations in this population and which may be related to fetal growth and development. 
42 We also considered potential confounding by maternal smoking during pregnancy; 
however, smoking data were missing for 13 women. Among women with complete data, the 
inclusion of maternal smoking during pregnancy (yes or no in months 1–6 of pregnancy) did 
not alter associations or conclusions. Thus, we have chosen to present associations which do 
not adjust for smoking to preserve our larger sample size.
We additionally investigated relationships between OPEs and dichotomous preterm birth 
using logistic regression models. Although our sample size was relatively large, preterm 
birth impacted only a small number of infants (n=43). To avoid over fitting models with 
limited data, dichotomized categories of exposure (above vs below the median) were used in 
preterm birth models rather than quartiles.
We hypothesize the potential pathway by which OPEs may impact birth could vary based on 
the sex of the child. In preliminary analyses we included a multiplicative interaction term 
(exposure * sex) in statistical models. We considered p<0.2 statistically suggestive of a sex 
difference the impact of OPE exposures. Based on interaction analyses, which suggested 
differences in associations by sex for several OPE metabolites (i.e. interaction p<0.2) and the 
prior literature suggesting sex-specific differences in the impact of endocrine disrupting 
chemicals on birth outcomes e.g. 40,48, we stratified all analyses to investigate sex-specific 
impacts of exposure. All analyses were conducted in SAS (Version 9.4; SAS Institute Inc, 
Cary, NC).
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Mothers averaged 29.6 years of age at the time of enrollment and were highly educated, with 
nearly 70% having a college education (Table 1). This was the first pregnancy for 
approximately half of the women included in analyses (47.6%); and the majority (55.6%) 
had a BMI within the normal range at the start of their pregnancy. Women included in the 
present study (Table 1) were more likely to be white, have higher educational attainment, 
and be older than mothers in the larger PIN cohort.41,42,49 Infants were born at an average of 
39.1 weeks gestation (range 29.0–42.6 weeks; standard deviation 1.84 weeks) and weighed 
an average of 3326 grams at birth (range 1422–4760 grams; standard deviation 526 grams). 
Birthweight-for-gestational age z-scores averaged 0.36 (range −2.02, 3.27; standard 
deviation 0.93). Women included in these analyses tended to be older and more highly 
educated than the PIN population as a whole and a greater percentage reported white race. A 
slightly smaller percentage of children in our sample were born preterm (12.3% vs. 14.6%) 
and a slightly higher percentage of children were born with low birthweight (9.9% vs 
10.6%) than in the larger PIN Study cohort.
Table 2 provides a summary of urinary OPE metabolite concentrations during pregnancy. 
Four urinary OPE metabolites, BDCIPP, DPHP, ip-PPP and BCIPHIPP, were detected in 
>83% of samples and concentrations varied considerably between women but distributions 
were similar for male and female infants. Additional analyses were not conducted for BCIPP 
and tb-PPP because they were detected infrequently in these samples (2.00–48.70% 
detection).
Birth Outcomes
Patterns of association between prenatal OPE metabolites and birth outcomes varied by 
infant sex. Female infants in the highest quartile of exposure to ip-PPP were born 1 week 
earlier than those in the first quartile (β=−1.00 week; 95% confidence interval (CI): −1.85, 
−0.15 weeks; p=0.02; Figure 1 and Supplemental Table 1). While similar patterns were 
observed for DPHP and BDCIPP, associations did not reach statistical significance. Among 
male infants, DPHP was associated with a modest increase in gestational duration. For 
example, baby boys with the highest levels of prenatal exposure were born approximately 5 
days later than those with the lowest levels of exposure (β=0.75 weeks; 95% CI: 0.01, 1.50 
weeks; p=0.05). Other metabolites were generally not associated with gestational age at 
delivery among males (i.e. associations were imprecisely estimated, did not follow a 
consistent pattern across the exposure gradient, and were not statistically significant).
Additional analyses were conducted to assess relationship between OPE metabolite levels 
and the odds of preterm birth. Among females, maternal ip-PPP and BDCIPP concentrations 
were associated with increased odds of preterm birth (Table 3). For example, women with 
ip-PPP concentrations above the median were 4.58 times as likely to deliver daughters 
preterm compared to those with lower maternal levels of ip-PPP (95% CI: 1.23, 17.06). 
Conversely, maternal urinary ip-PPP concentrations were associated with decreased odds of 
preterm birth among male infants (odds ratio (OR)=0.21; 95% CI: 0.06, 0.68).
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Similar patterns were observed between OPE metabolites and birthweight (among all births; 
Table 4); however we found little evidence for associations between prenatal exposure to 
OPEs and birthweight-for-gestational age z-scores for either male or female infants 
suggesting any growth impacts were driven by shorter gestational duration (Table 5). Among 
females, z-scores decreased with increasing ip-PPP quartile, but all 95% confidence intervals 
crossed the null. No clear patterns were observed for other metabolites or among males.
Discussion
The vast majority of pregnant women included in our study population had detectable levels 
of several OPE metabolites in samples of their urine. Our results suggest that prenatal 
exposure to some of these OPEs could be associated with altered timing of birth. Among 
girls, patterns suggested decreased gestational duration and increased odds of preterm (birth 
at <37 weeks gestation), particularly for ip-PPP and BDCIPP. Clinical preterm birth and 
decreased gestational duration--even among full-term infants--is associated with increased 
risk of numerous adverse health outcomes.50–53 In addition to being the primary cause of 
mortality in the first year of life, preterm birth has been associated with poorer 
neurodevelopment, respiratory disease, cardiovascular disease and metabolic disorders later 
in life. 50–58
Conversely, our results suggest that maternal DPHP concentrations may be associated with 
increased gestational duration among male infants. Although increased gestational duration 
is generally considered beneficial, post-term birth (occurring after 42 weeks gestation) 
carries health risks for both the infants and mother.59 Although boys with higher levels of 
exposure to DPHP were born later, births at 42 weeks gestation or after were extremely 
uncommon in this cohort, potentially because included mothers had access to medical care 
and interventions to prevent post-term birth.
Reasons for differences in the pattern of association between males and females are unclear. 
In general, male infants are more likely to be born preterm than females, which has been 
attributed to a variety of factors, including the relatively greater weight of male infants at 
earlier gestational ages, increased susceptibility to infection or pregnancy complication 
among women carrying male fetuses, or differential impacts of environmental exposure by 
fetal sex.60–64 However, our findings suggest that female infants may be more susceptible to 
OPE exposure, at least with respect to preterm birth. Recent work investigating brominated 
flame retardants suggests that the placenta responds differently to exposure to exogenous 
chemicals based on the sex of the infant. 65 Placenta samples associated with male infants 
had higher concentrations of brominated flame retardants, despite no differences in maternal 
serum concentrations. Impacts on thyroid hormones and metabolic enzymes in placenta also 
differed by sex, suggesting the placenta may mediate the impacts of environmental 
chemicals. 65 Other research demonstrates that exposure to phthalates is associated with 
molecular changes in placental tissue in sexually dimorphic ways. 66 Though OPEs have 
been reported in placental tissues16–18, it remains unclear whether sex specific impacts 
extend to OPEs or preterm birth.
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Although patterns of association were similar for birthweight, associations appeared to be 
driven by differences in gestational age; birthweight-for-gestational age z-scores were not 
significantly associated with measures of OPE exposure. This suggests that impact of OPEs 
on birthweight is mediated by pregnancy duration and not decreased growth. To our 
knowledge, impacts of OPE exposure on preterm birth risk have not been investigated 
previously in a human population. Among chicken embryos, higher exposure to TDCIPP 
appeared to delay pipping time (i.e. number of hours of incubation required by the embryo 
to form a pipping star), although relationships were not statistically significant. 29 The same 
study demonstrated decreased body weight and a shorter head plus bill length among highly 
exposed chicks, suggesting that early exposure could impact growth and development.29 
Past studies investigating impacts of gestational exposure in rodents have reported decreased 
birthweight with exposure to OPEs, but did not specifically considered the potential drivers 
of lower body weights (e.g. growth restriction or earlier birth). Differences in species and 
dosing complicate comparisons of our findings with these results. It is possible that our 
results are consistent with these studies; however, additional data using animal systems 
designed to investigate timing of birth is needed to elucidate potential relationships as are 
data from other human cohorts.
Given the potential relationships identified with altered gestational duration in this cohort, it 
is important to consider recent data suggesting that levels of exposure to OPE may have 
increased since 2002–2005 (when samples were collected in this cohort). We recently 
reported that urinary BDCIPP concentrations were 15 times higher in samples collected in 
2015 than those collected in 2002.12 Increases in DPHP were less dramatic, but suggest that 
levels of exposure in the 2010s likely exceed those observed for the majority of women in 
the PIN cohort. Temporal trends for other OPE metabolites, including ip-PPP, have yet to be 
evaluated; however, urinary ip-PPP concentrations among the women in this cohort were 
substantially higher than those observed among women in the CHAMACOS cohort, a 
pregnancy cohort of Mexican American women from California giving birth 2000–2001 and 
providing urine samples at approximately the same gestational week as the women in the 
PIN cohort (i.e. geometric mean ip-PPP PIN=6.80 and CHAMACOS=0.33 ng/mL).67 There 
are certainly many differences between PIN and CHAMACOS which could explain 
differences in urinary ip-PPP and as such we caution against the over interpretation of higher 
urinary levels among PIN women.
Although our samples size was relatively large, there were only 43 preterm births in our 
cohort. As a result, we treated preterm birth as a single outcome which is likely an 
oversimplification of a complex outcome. McElrath et al. 2008 hypothesized that preterm 
birth could be divided into two sets of proximal causes, intrauterine inflammation (preterm 
labor, preterm membrane rupture, placental abruption, and cervical insufficiency) and 
abnormal placentation (preeclampsia and intrauterine growth restriction). 68 Investigating 
preterm birth as a heterogeneous outcome would require a large study population but could 
provide additional insights regarding the potential mechanisms leading to altered gestational 
timing and preterm birth.69
Our analyses are additionally limited by our reliance on a single spot urine sample to 
characterize exposure to OPEs during the prenatal period. Although our previous work 
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among pregnant women suggests that spot urine BDCIPP and DPHP levels are moderately 
correlated throughout the course of pregnancy,70 the reliability of spot ip-PPP and 
BCIPHIPP concentrations has yet to be evaluated. In addition, the timing of the urine sample 
collection (between 24 and 30 weeks gestation) for OPE assessment could have resulted in 
some preterm births being excluded from these analyses. If higher levels of exposures are 
truly related to preterm birth, it is possible that the most impacted infants were excluded 
(reducing estimated odds ratios). The PIN women included in our current analyses are not 
representative of the general population (e.g. they were highly educated mainly non-
Hispanic white women), suggesting that the generalizability of our results to other 
populations could be limited. However, we do not anticipate that this would limit the validity 
of our findings. In fact, we consider the homogeneity of our study population a possible 
strength as it may reduce the impact of unmeasured confounding. Nonetheless, residual 
confounding remains a possible explanation for our results. In addition, we used urinary 
metabolite levels as indicators of exposure to OPEs, an assumption that is more reasonable 
for some OPEs than others. For example, BDCIPP is a primarily metabolite of TDCIPP and 
is not known to be used in consumer products or applications. However, DPHP can be 
formed from metabolism of several organophosphate compounds, including TPHP, but is 
also produced and used in consumer products. Regardless of the source or pathway of 
exposure, our results suggest a relationship between measures of these compounds in urine 
and birth outcomes. Additional research is needed to understand sources of exposure for 
pregnant women as well as the potential health impacts of exposure among these women and 
their unborn children.
Conclusions
Cumulatively, our results indicate that prenatal OPE exposure may impact timing of birth, 
suggesting a possible link with life-long health. Given the widespread exposure to these 
compounds, and predicted increases in their use in the coming decades, further research 
investigating relationships is warranted.
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• Organophosphate ester metabolites were frequently detected in pregnant 
women’s urine.
• BDCIPP and ip-PPP were associated with shorter gestation among female 
infants.
• Urinary ip-PPP was associated with longer gestation among male infants.
• OPEs were associated with birthweight; impacts appear driven by gestational 
length.
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Mean difference in gestational age at the time of delivery by quartile of OPE exposure 
(indicated by maternal urinary metabolite concentrations). Analyses adjusted for maternal 
age, race, education, parity, pre-pregnancy BMI and season of urine sample collection. A 
table format of these data is shown in Supplemental Table 1.
Hoffman et al. Page 14

























Hoffman et al. Page 15
Table 1




 ≤25 76 (21.8)
 26–30 126 (36.1)
 31–35 107 (30.7)
 ≥36 40 (11.5)
Race
 white 278 (79.7)
 non-white 71 (20.3)
Education (years)
 ≤15 106 (30.4)
 ≥16 243 (69.6)
Parity
 0 166 (47.6)
 ≥1 183 (52.4)
Pre-pregnancy BMI
 BMI<18.5 - Underweight 46 (13.2)
 18.5≤BMI<24.9 - Normal range 194 (55.6)
 24.9≤BMI<29.9 - Overweight 42 (12.0)
 29.9≤BMI - Obese 67 (19.2)
Smoking During Pregnancy
 Yes 29 (8.3)
 No 307 (88.0)
 Missing 13 (3.7)
Sex of the Child
 Male 192 (55.0)
 Female 157 (45.0)
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Table 3
Odds ratio for preterm birth (<37 weeks gestation) comparing maternal OPE metabolite levels above the 
median (Quartile 3+Quartile 4) to those below (Quartile 1+ Quartile 2). Analyses adjusted for maternal age, 





OPE Metabolite OR 95% CI OR 95% CI
BDCIPP 3.99 1.08, 14.78 0.76 0.25, 2.32
DPHP 1.11 0.37, 3.38 0.46 0.17, 1.25
ip-PPP 4.58 1.23, 17.06 0.21 0.06, 0.68
BCIPHIPP 0.64 0.20, 2.02 1.06 0.40, 2.82
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Environ Int. Author manuscript; available in PMC 2019 July 01.
